Impact of ATO on outcome in low/intermediate-risk and high-risk patients with newly diagnosed APL
| Regimens . | Number . | Survivals . | P value . | HR for inferior survival . | 95% CI . |
|---|---|---|---|---|---|
| Low/intermediate risk | 432 | ||||
| 60-d survival | |||||
| ATRA/chemotherapy | 285 | 94.7% | .22 | 1.97 | 0.65-5.93 |
| ATRA/IV-ATO and oral-AAA | 147 | 97.3% | 0.51 | 0.17-1.53 | |
| Post–60-d OS (5 y) | |||||
| ATRA/chemotherapy | 265 | 91.4% | .99 | 1.0 | 0.45-2.23 |
| ATRA/IV-ATO and oral-AAA | 137 | 95.2% | 1.0 | 0.45-2.23 | |
| ATRA/chemotherapy/non-ATO maintenance | 174 | 90.4% | .94 | 1.28 | 0.37-4.37 |
| ATRA/chemotherapy/oral-AAA maintenance | 91 | 93.2% | 0.92 | 0.46-1.81 | |
| ATRA/IV-ATO | 40 | 95.5% | 0.92 | 0.46-1.81 | |
| Oral-AAA | 97 | 95.3% | 0.85 | 0.32-2.29 | |
| RFS (5 y) | |||||
| ATRA/chemotherapy | 270 | 78.6% | <.001 | 6.54 | 2.37-18.01 |
| ATRA/IV-ATO and oral-AAA | 143 | 95.7% | 0.15 | 0.06-0.42 | |
| ATRA/chemotherapy/non-ATO maintenance | 179 | 72.8% | <.001 | 7.54 | 3.39-19.20 |
| ATRA/chemotherapy/oral-AAA maintenance | 91 | 88.8% | 0.39 | 0.21-0.73 | |
| ATRA/IV-ATO | 42 | 93.1% | 0.20 | 0.05-0.85 | |
| Oral-AAA | 101 | 96.8% | 0.08 | 0.02-0.34 | |
| OS (5 y) | |||||
| ATRA/chemotherapy | 285 | 86.3% | .50 | 1.24 | 0.66-2.32 |
| ATRA/IV-ATO and oral-AAA | 147 | 92.0% | 0.81 | 0.43-1.52 | |
| High risk | 199 | ||||
| 60-d survival | |||||
| ATRA/chemotherapy | 135 | 84.4% | .03 | 3.45 | 1.03-11.55 |
| ATRA/IV-ATO and oral-AAA | 64 | 95.3% | 0.29 | 0.09-0.97 | |
| Post–60-d survival (5 y) | |||||
| ATRA/chemotherapy | 112 | 94.9% | .85 | 1.13 | 0.31-4.16 |
| ATRA/IV-ATO and oral-AAA | 59 | 96.6% | 0.88 | 0.24-3.23 | |
| ATRA/chemotherapy/non-ATO maintenance | 78 | 95.5% | .47 | 2.38 | 0.50-11.49 |
| ATRA/chemotherapy/oral-AAA maintenance | 34 | 94.1% | 0.40 | 0.05-3.23 | |
| ATRA/IV-ATO | 18 | 94.4% | 1.05 | 0.38-2.92 | |
| Oral-AAA | 41 | 97.6% | 0.40 | 0.05-3.23 | |
| RFS (5 y) | |||||
| ATRA/chemotherapy | 113 | 78.0% | .002 | 11.48 | 1.55-85.00 |
| ATRA/IV-ATO and oral-AAA | 60 | 98.3% | 0.09 | 0.01-0.65 | |
| ATRA/chemotherapy/non-ATO maintenance | 79 | 74.5% | .01 | 1.00 | |
| ATRA/chemotherapy/oral-AAA maintenance | 34 | 85.1% | 0.47 | 0.18-1.26 | |
| ATRA/IV-ATO | 17 | 94.1% | 0.29 | 0.04-2.18 | |
| Oral-AAA | 43 | 100% | 0.00 | NE | |
| OS (5 y) | |||||
| ATRA/chemotherapy | 135 | 80.1% | .06 | 2.23 | 0.93-5.36 |
| ATRA/IV-ATO and oral-AAA | 64 | 92.1% | 0.45 | 0.19-1.08 |
| Regimens . | Number . | Survivals . | P value . | HR for inferior survival . | 95% CI . |
|---|---|---|---|---|---|
| Low/intermediate risk | 432 | ||||
| 60-d survival | |||||
| ATRA/chemotherapy | 285 | 94.7% | .22 | 1.97 | 0.65-5.93 |
| ATRA/IV-ATO and oral-AAA | 147 | 97.3% | 0.51 | 0.17-1.53 | |
| Post–60-d OS (5 y) | |||||
| ATRA/chemotherapy | 265 | 91.4% | .99 | 1.0 | 0.45-2.23 |
| ATRA/IV-ATO and oral-AAA | 137 | 95.2% | 1.0 | 0.45-2.23 | |
| ATRA/chemotherapy/non-ATO maintenance | 174 | 90.4% | .94 | 1.28 | 0.37-4.37 |
| ATRA/chemotherapy/oral-AAA maintenance | 91 | 93.2% | 0.92 | 0.46-1.81 | |
| ATRA/IV-ATO | 40 | 95.5% | 0.92 | 0.46-1.81 | |
| Oral-AAA | 97 | 95.3% | 0.85 | 0.32-2.29 | |
| RFS (5 y) | |||||
| ATRA/chemotherapy | 270 | 78.6% | <.001 | 6.54 | 2.37-18.01 |
| ATRA/IV-ATO and oral-AAA | 143 | 95.7% | 0.15 | 0.06-0.42 | |
| ATRA/chemotherapy/non-ATO maintenance | 179 | 72.8% | <.001 | 7.54 | 3.39-19.20 |
| ATRA/chemotherapy/oral-AAA maintenance | 91 | 88.8% | 0.39 | 0.21-0.73 | |
| ATRA/IV-ATO | 42 | 93.1% | 0.20 | 0.05-0.85 | |
| Oral-AAA | 101 | 96.8% | 0.08 | 0.02-0.34 | |
| OS (5 y) | |||||
| ATRA/chemotherapy | 285 | 86.3% | .50 | 1.24 | 0.66-2.32 |
| ATRA/IV-ATO and oral-AAA | 147 | 92.0% | 0.81 | 0.43-1.52 | |
| High risk | 199 | ||||
| 60-d survival | |||||
| ATRA/chemotherapy | 135 | 84.4% | .03 | 3.45 | 1.03-11.55 |
| ATRA/IV-ATO and oral-AAA | 64 | 95.3% | 0.29 | 0.09-0.97 | |
| Post–60-d survival (5 y) | |||||
| ATRA/chemotherapy | 112 | 94.9% | .85 | 1.13 | 0.31-4.16 |
| ATRA/IV-ATO and oral-AAA | 59 | 96.6% | 0.88 | 0.24-3.23 | |
| ATRA/chemotherapy/non-ATO maintenance | 78 | 95.5% | .47 | 2.38 | 0.50-11.49 |
| ATRA/chemotherapy/oral-AAA maintenance | 34 | 94.1% | 0.40 | 0.05-3.23 | |
| ATRA/IV-ATO | 18 | 94.4% | 1.05 | 0.38-2.92 | |
| Oral-AAA | 41 | 97.6% | 0.40 | 0.05-3.23 | |
| RFS (5 y) | |||||
| ATRA/chemotherapy | 113 | 78.0% | .002 | 11.48 | 1.55-85.00 |
| ATRA/IV-ATO and oral-AAA | 60 | 98.3% | 0.09 | 0.01-0.65 | |
| ATRA/chemotherapy/non-ATO maintenance | 79 | 74.5% | .01 | 1.00 | |
| ATRA/chemotherapy/oral-AAA maintenance | 34 | 85.1% | 0.47 | 0.18-1.26 | |
| ATRA/IV-ATO | 17 | 94.1% | 0.29 | 0.04-2.18 | |
| Oral-AAA | 43 | 100% | 0.00 | NE | |
| OS (5 y) | |||||
| ATRA/chemotherapy | 135 | 80.1% | .06 | 2.23 | 0.93-5.36 |
| ATRA/IV-ATO and oral-AAA | 64 | 92.1% | 0.45 | 0.19-1.08 |
NE, not evaluable.